


Claims

1. A compound of formula (I)



- 5 in which

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W, Y and Z represents CR²

or,

- 10 V represents N, and W, Y and Z independently of each other represent CH or CR²,

or,

V and Y represent N, and W and Z independently of each other represent CH or CR²,

R¹ represents a group selected from:

- 15 C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₆-cycloalkyl,
(C₁-C₃-alkoxy)-(C₂-C₃-alkyl)-, and (C₃-C₆-cycloalkyl)-(C₁-C₃-alkyl)-,

R² represents, independently of each other, halogen or a group selected from:

- 20 C₁-C₃-alkyl, C₃-C₄-cycloalkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy,
C₁-C₃-haloalkoxy, -N(H)C(=O)-(C₁-C₃-alkyl), -N(H)C(=O)H,
-N(H)C(=O)-(C₁-C₃-hydroxyalkyl),
-N(H)C(=O)-(C₁-C₃-alkyl)-(C₁-C₃-alkoxy), -N(H)C(=O)-phenyl,
-N(H)C(=O)-(C₃-C₄-cycloalkyl),
-N(H)C(=O)-(C₁-C₃-alkyl)-(C₃-C₄-cycloalkyl), and -N(H)C(=O)N(H)R⁸,

said -N(H)C(=O)-phenyl being optionally substituted at the phenyl ring, one, two or three times, identically or differently, with a substituent selected from:

halogen, hydroxy, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₄-cycloalkyl, and C₃-C₄-cycloalkyloxy,

said -N(H)C(=O)-(C₃-C₄-cycloalkyl) being optionally substituted at the C₃-C₄-cycloalkyl ring with a substituent selected from: fluorine, chlorine, trifluoromethyl, and methoxy,

R³ represents a group selected from:

C₂-C₆-hydroxyalkyl, and R⁴,

said C₂-C₆-hydroxyalkyl groups being optionally substituted with one, two or three halogen atoms selected from:

fluorine, and chlorine,

R⁴ represents -(C₂-C₆-alkyl)-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

in which C₂-C₆-alkyl is optionally substituted with one, two or three halogen atoms selected from:

fluorine, and chlorine,

R⁵ and R⁷ independently of each other represent hydrogen (glycine) or a group selected from:

-CH₃ (alanine), -C(H)(CH₃)₂ (valine), -(CH₂)₂CH₃ (norvaline), -CH₂C(H)(CH₃)₂ (leucine), -C(H)(CH₃)CH₂CH₃ (isoleucine), -(CH₂)₃CH₃ (norleucine), -C(CH₃)₃ (2-*tert*-butylglycine), benzyl (phenylalanine), 4-hydroxybenzyl (tyrosine), -(CH₂)₃NH₂ (ornithine), -(CH₂)₄NH₂ (lysine), -(CH₂)₂C(H)(OH)CH₂NH₂ (hydroxylysine), -CH₂OH (serine), -(CH₂)₂OH (homoserine), -C(H)(OH)CH₃ (threonine), -(CH₂)₃N(H)C(=NH)NH₂ (arginine), -(CH₂)₃N(H)C(=O)NH₂ (citrulline), -CH₂C(=O)NH₂ (asparagine), -CH₂C(=O)OH (aspartic acid), -(CH₂)₂C(=O)OH (glutamic acid), -(CH₂)₂C(=O)NH₂ (glutamine), -CH₂SH (cysteine), -(CH₂)₂SH (homocysteine), -(CH₂)₂SCH₃ (methionine), -CH₂SCH₃ (S-methylcysteine), (1*H*-imidazol-4-yl)methyl- (histidine), (1*H*-indol-3-yl)methyl- (tryptophan), -CH₂NH₂ (2,3-diaminopropanoic acid), and -(CH₂)₂NH₂ (2,4-diaminobutanoic acid),

R⁶ represents hydrogen or a group selected from:

C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₂-C₃-hydroxyalkyl, C₃-C₄-cycloalkyl,
(C₃-C₄-cycloalkyl)-(C₁-C₃-alkyl)-, and (C₁-C₃-alkoxy)-(C₂-C₃-alkyl)-,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said
N-oxide, tautomer or stereoisomer.

2. The compound of formula (I) according to claim 1,
wherein

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W,
Y and Z represents CR²

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

R¹ represents a group selected from:

C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₃-C₄-cycloalkyl,
(C₁-C₃-alkoxy)-(C₂-C₃-alkyl)-, and (C₃-C₄-cycloalkyl)-(C₁-C₃-alkyl)-,

R² represents, independently of each other, halogen or a group selected from:

C₁-C₃-alkyl, C₃-C₄-cycloalkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy,
C₁-C₃-haloalkoxy, -N(H)C(=O)-(C₁-C₃-alkyl), -N(H)C(=O)H,
-N(H)C(=O)-(C₁-C₃-hydroxyalkyl),
-N(H)C(=O)-(C₁-C₃-alkyl)-(C₁-C₃-alkoxy), -N(H)C(=O)-phenyl,
-N(H)C(=O)-(C₃-C₄-cycloalkyl),
-N(H)C(=O)-(C₁-C₃-alkyl)-(C₃-C₄-cycloalkyl), and -N(H)C(=O)N(H)R⁸,

said -N(H)C(=O)-phenyl being optionally substituted at the phenyl ring,
one, two or three times, identically or differently, with a substituent
selected from:

halogen, hydroxy, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,
C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₄-cycloalkyl, and
C₃-C₄-cycloalkyloxy,

said -N(H)C(=O)-(C₃-C₄-cycloalkyl) being optionally substituted at the C₃-
C₄-cycloalkyl ring with a substituent selected from:

fluorine, chlorine, trifluoromethyl, and methoxy,

R³ represents a group selected from:

C₂-C₆-hydroxyalkyl, and R⁴,

said C₂-C₆-hydroxyalkyl groups being optionally substituted with one, two or three halogen atoms selected from:

5 fluorine, and chlorine,

R⁴ represents -(C₂-C₆-alkyl)-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

in which C₂-C₆-alkyl is optionally substituted with one, two or three halogen atoms selected from:

10 fluorine, and chlorine,

R⁵ and R⁷ independently of each other represent hydrogen (glycine) or a group selected from:

-CH₃ (alanine), -C(H)(CH₃)₂ (valine), -(CH₂)₂CH₃ (norvaline), -CH₂C(H)(CH₃)₂ (leucine), -C(H)(CH₃)CH₂CH₃ (isoleucine), -(CH₂)₃CH₃ (norleucine), -C(CH₃)₃ (2-*tert*-butylglycine), benzyl (phenylalanine), 4-hydroxybenzyl (tyrosine), -
 15 (CH₂)₃NH₂ (ornithine), -(CH₂)₄NH₂ (lysine), -(CH₂)₂C(H)(OH)CH₂NH₂ (hydroxylysine), -CH₂OH (serine), -(CH₂)₂OH (homoserine), -C(H)(OH)CH₃ (threonine), -(CH₂)₃N(H)C(=NH)NH₂ (arginine), -(CH₂)₃N(H)C(=O)NH₂ (citrulline),
 20 -CH₂C(=O)NH₂ (asparagine), -CH₂C(=O)OH (aspartic acid), -(CH₂)₂C(=O)OH (glutamic acid), -(CH₂)₂C(=O)NH₂ (glutamine), -CH₂SH (cysteine), -(CH₂)₂SH (homocysteine), -(CH₂)₂SCH₃ (methionine), -CH₂SCH₃ (S-methylcysteine), (1*H*-imidazol-4-yl)methyl- (histidine), (1*H*-indol-3-yl)methyl- (thryptophan), -CH₂NH₂ (2,3-diaminopropanoic acid), and -(CH₂)₂NH₂ (2,4-diaminobutanoic acid),

25

R⁸ represents hydrogen or a group selected from:

C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₂-C₃-hydroxyalkyl, C₃-C₄-cycloalkyl, (C₃-C₄-cycloalkyl)-(C₁-C₃-alkyl)-, and (C₁-C₃-alkoxy)-(C₂-C₃-alkyl)-,

30 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

3. The compound of formula (I) according to claim 1 or 2,

35 wherein

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W, Y and Z represents CR²

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

5

R¹ represents a group selected from:
C₁-C₃-alkyl, C₁-C₃-haloalkyl, and C₃-C₄-cycloalkyl,

R² represents, independently of each other, halogen or a group selected from:
10 C₁-C₃-alkyl, C₃-C₄-cycloalkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy,
C₁-C₃-haloalkoxy, -N(H)C(=O)-(C₁-C₃-alkyl), -N(H)C(=O)H,
-N(H)C(=O)-(C₁-C₃-hydroxyalkyl),
-N(H)C(=O)-(C₁-C₃-alkyl)-(C₁-C₃-alkoxy), -N(H)C(=O)-phenyl,
-N(H)C(=O)-(C₃-C₄-cycloalkyl),
15 -N(H)C(=O)-(C₁-C₃-alkyl)-(C₃-C₄-cycloalkyl), and -N(H)C(=O)N(H)R³,
said -N(H)C(=O)-phenyl being optionally substituted at the phenyl ring,
one, two or three times, identically or differently, with a substituent
selected from:
halogen, hydroxy, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,
20 C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₄-cycloalkyl, and
C₃-C₄-cycloalkyloxy,
said -N(H)C(=O)-(C₃-C₄-cycloalkyl) being optionally substituted at the C₃-
C₄-cycloalkyl ring with a substituent selected from:
fluorine, chlorine, trifluoromethyl, and methoxy,

25

R³ represents a group selected from:
C₂-C₆-hydroxyalkyl, and R⁴,
said C₂-C₆-hydroxyalkyl group being optionally substituted with one, two
or three halogen atoms selected from:
30 fluorine, and chlorine,

30

R⁴ represents -(C₂-C₆-alkyl)-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,
in which C₂-C₆-alkyl is optionally substituted with one, two or three
halogen atoms selected from:
35 fluorine, and chlorine,

35

R⁵ and R⁷ independently of each other represent a group selected from:
-CH₃ (alanine), -C(H)(CH₃)₂ (valine), -(CH₂)₂CH₃ (norvaline), -(CH₂)₃NH₂
(ornithine), -(CH₂)₄NH₂ (lysine), and -(CH₂)₃N(H)C(=NH)NH₂ (arginine),

5 R⁸ represents hydrogen or a group selected from:
C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₂-C₃-hydroxyalkyl, C₃-C₄-cycloalkyl,
(C₃-C₄-cycloalkyl)-(C₁-C₃-alkyl)-, and (C₁-C₃-alkoxy)-(C₂-C₃-alkyl)-,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said
10 N-oxide, tautomer or stereoisomer.

4. The compound of formula (I) according to any of claims 1 to 3,
wherein

15 V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W,
Y and Z represents CR²

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

20

R¹ represents a C₁-C₃-alkyl group,

R² represents, independently of each other, halogen or a group selected from:
C₁-C₃-alkyl, C₃-C₄-cycloalkyl, C₁-C₃-haloalkyl, C₁-C₃-alkoxy,
25 and -N(H)C(=O)-(C₁-C₃-alkyl),

R³ represents a group selected from:
C₂-C₆-hydroxyalkyl, and R⁴,

30 R⁴ represents -(C₂-C₆-alkyl)-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

R⁵ and R⁷ independently of each other represent a group selected from:
-CH₃ (alanine), and -(CH₂)₄NH₂ (lysine),

35 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said
N-oxide, tautomer or stereoisomer.

5. The compound of formula (I) according to any of claims 1 to 4,
wherein

5

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W,
Y and Z represents CR²

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

10

R¹ represents a methyl group,

R² represents, independently of each other, fluorine, chlorine or a group selected
from:

15

methyl, cyclopropyl, difluoromethyl, methoxy, and -N(H)C(=O)-CH₃,

R³ represents a group selected from:
-(CH₂)₂OH, and R⁴,

20

R⁴ represents -(CH₂)₂-OC(=O)-C(H)(R⁵)-N(H)C(=O)-C(H)(R⁷)-NH₂,

R⁵ represents -CH₃ (alanine),

R⁷ represents -(CH₂)₄NH₂ (lysine),

25

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said
N-oxide, tautomer or stereoisomer.

30

6. The compound of formula (I) according to any of claims 1 to 5,
wherein

V, W, Y and Z independently of each other represent CH or CR², wherein one of V, W,
Y and Z represents CR²

35

or,

V represents N, and W, Y and Z independently of each other represent CH or CR²,

R¹ represents a methyl group,

R² represents, independently of each other, fluorine, chlorine or a group selected from:

methyl, cyclopropyl, difluoromethyl, methoxy, -N(H)C(=O)-CH₃,
-N(H)C(=O)-cyclopropyl, and -N(H)C(=O)N(H)-cyclopropyl,

R³ represents a -(CH₂)₂OH group,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

7. Compounds of formula (I) according to any of claims 1 to 6, which is selected from the group consisting of:

2-{4-[(3-{4-[(3-chloropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}acetamide ,

2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

2-{3,5-difluoro-4-[(3-{4-[(3-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,

2-{4-[(3-{4-[(2-(difluoromethyl)pyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,

2-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,

2-{4-[(3-{4-[(3-cyclopropylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,

2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-4-[(2-methylpyrimidin-4-

yl)amino]pyrimidin-5-ol
2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{4-[(5-fluoro-2-methylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-(pyrimidin-4-ylamino)pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethanol
N-[4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1H-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]-5-methylpyridin-2-yl]acetamide ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate,
N-[4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1H-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl]cyclopropanecarboxamide ,
1-cyclopropyl-3-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1H-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}urea ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(3-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-[5-methoxy-4-[(5-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}ethanol ,
3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy}propan-1-ol ,
3-{3,5-difluoro-4-[(3-[5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}propan-1-ol ,
3-{3,5-difluoro-4-[(3-[5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}propan-1-ol ,
(2R)-3-{3,5-difluoro-4-[(3-[5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl]-1H-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,
(2R)-3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy}-2-methylpropan-1-ol ,
N-[4-[(2-{1-[2,6-difluoro-4-[(2R)-3-hydroxy-2-methylpropyl]oxy}benzyl]-1H-indazol-3-

yl]-5-methoxypyrimidin-4-yl]amino)pyridin-2-yl]acetamide ,
 (2R)-3-[3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]-2-methylpropan-1-ol ,
 3-[3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]propan-1-ol ,
 2-[4-[(3-{4-[(2,6-dimethylpyrimidin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy]ethanol ,
 2-[3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethyl D-lysyl-L-alaninate, salt with trifluoroacetic acid ,
 2-[3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethyl D-lysyl-L-alaninate ,
 2-[3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid , and
 2-[3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethyl L-lysyl-L-alaninate with trifluoroacetic acid ,
 or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

- 5 8. Compounds of formula (I) according to any of claims 1 to 7, which is selected from the group consisting of:


2-[4-[(3-{4-[(3-chloropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy]ethanol ,
 2-[3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethanol ,
 2-[3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethanol ,
N-[4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1H-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl]acetamide ,
 2-[3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethanol ,
 2-[3,5-difluoro-4-[(3-{4-[(3-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy]ethanol ,
 2-[4-[(3-{4-[(2-(difluoromethyl)pyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy]ethanol ,
 2-[4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-

yl)methyl]-3,5-difluorophenoxy}ethanol ,
2-{4-[(3-{4-[(3-cyclopropylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,
2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-5-ol
2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{4-[(5-fluoro-2-methylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-(pyrimidin-4-ylamino)pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol
N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]-5-methylpyridin-2-yl}acetamide ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,
N-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}cyclopropanecarboxamide ,
1-cyclopropyl-3-{4-[(2-{1-[2,6-difluoro-4-(2-hydroxyethoxy)benzyl]-1*H*-indazol-3-yl}-5-methoxypyrimidin-4-yl)amino]pyridin-2-yl}urea ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
2-{3,5-difluoro-4-[(3-{5-methoxy-4-[(5-methoxy-2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}ethanol ,
3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}propan-1-ol ,
3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}propan-1-ol ,
3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}propan-1-ol ,
(2*R*)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyrimidin-4-yl)amino]pyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,
(2*R*)-3-{4-[(3-{4-[(2,5-dimethylpyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1*H*-indazol-1-yl)methyl]-3,5-difluorophenoxy}-2-methylpropan-1-ol ,
N-[4-[(2-{1-(2,6-difluoro-4-[(2*R*)-3-hydroxy-2-methylpropyl]oxy}benzyl)-1*H*-indazol-3-

yl]-5-methoxypyrimidin-4-yl)amino)pyridin-2-yl]acetamide ,
 (2R)-3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(3-methoxypyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}-2-methylpropan-1-ol ,
 3-{3,5-difluoro-4-[(3-{5-methoxy-4-[(2-methylpyridin-4-yl)amino]pyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}propan-1-ol ,
 2-{4-[(3-{4-[(2,6-dimethylpyrimidin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]-3,5-difluorophenoxy}ethanol ,
 2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethyl D-lysyl-L-alaninate, salt with trifluoroacetic acid ,
 and
 2-{3,5-difluoro-4-[(3-{4-[(2-fluoropyridin-4-yl)amino]-5-methoxypyrimidin-2-yl}-1H-indazol-1-yl)methyl]phenoxy}ethyl L-lysyl-L-alaninate, salt with trifluoroacetic acid ,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

- 5 9. A method of preparing a compound of general formula (1a), said method comprising the step of allowing an intermediate compound of general formula (1-9) :




(1-9)

10

in which R¹, V, W, Y and Z are as defined in any one of claims 1 to 8, and R⁹ represents a methyl- or an ethyl group or an alcohol protecting group, such as *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl,

to react with a deprotection agent, such as a dealkylating agent, for example, boron trichloride,


5 thereby giving a compound of general formula (Ia) :



(Ia)

10 in which R¹, V, W, Y and Z are as defined in any one of claims 1 to 8.


10. A method of preparing a compound of general formula (Ib), said method comprising the step of allowing an intermediate compound of general formula (1-20) :



in which R^1 , R^5 , R^7 , V, W, Y and Z are as defined in any one of claims 1 to 8, and PG represents an amino protecting group, such as, for example fluorenylmethyloxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl or *tert*-butyloxycarbonyl,

to react with a Broensted acid, such as, for example trifluoroacetic acid,

thereby giving a compound of general formula (Ib) :



in which R^1 , R^5 , R^7 , V, W, Y and Z are as defined in any one of claims 1 to 8.

11. A compound of general formula (I) according to any of claims 1 to 8 for use in the treatment or prophylaxis of a disease.

12. Use of a compound of general formula (I) according to any of claims 1 to 8 in the manufacture of a medicament for the treatment or prophylaxis of a disease, whereby the disease is a hyperproliferative disease and/or a disorder responsive to induction of cell death.

13. Use of a compound of general formula (I) according to claim 12, whereby the hyperproliferative disease and/or disorder responsive to induction of cell death is a haematological tumour, a solid tumours and/or metastases thereof.


14. Use of a compound of general formula (I) according to claim 13, whereby the hyperproliferative disease is cervical cancer.

15. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 8, together with at least one pharmaceutically acceptable carrier or auxiliary.

16. Use of a composition according to claim 15 in the manufacture of a medicament for the treatment of a haematological tumour, a solid tumour and/or metastases thereof.


17. A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 8, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.

18. A compound of formula (1-9):




in which R¹, V, W, Y and Z are as defined in any one of claims 1 to 8, and R⁹ represents a methyl- or an ethyl group or an alcohol protecting group, such as for example *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl, triethylsilyl, triisopropylsilyl or tetrahydropyranyl.

19. A compound of formula (1-20) :




in which R¹, R⁵, R⁷, V, W, Y and Z are as defined any one of claims 1 to 8, and PG represents an amino protecting group, such as, for example
 5 fluorenylmethyloxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl or *tert*-butyloxycarbonyl.

20. The use of a compound of formula 1-9 as defined in claim 18, for the preparation of a compound of general formula (Ia)



in which R¹, V, W, Y and Z are as defined in any one of claims 1 to 8.

21. The use of a compound of formula 1-20 as defined in claim 19, for the preparation
 15 of a compound of general formula (Ib)



in which R¹, R⁵, R⁷, V, W, Y and Z are as defined in any one of claims 1 to 8.